Table II.
Summary of Outcomes
| Total | Other PTCL | CTCL | |
|---|---|---|---|
| Outcome | N (%) | N (%) | N (%) |
| Number of patients (N) | 37 | 24 | 13 |
| aGVHD | |||
| Yes | 19 (51.4) | 12 (50.0) | 7 (53.9) |
| Grade I | 5 (13.5) | 4 (16.7) | 1 (7.7) |
| Grade II | 8 (21.6) | 6 (25.0) | 2 (15.4) |
| Grade III | 2 (5.4) | 1 (4.2) | 1 (7.7) |
| Grade IV | 4 (10.8) | 1 (4.2) | 3 (23.1) |
| No | 18 (48.6) | 12 (50.0) | 6 (46.2) |
| cGVHD | |||
| Yes | 23 (62.2) | 16 (66.7) | 7 (53.9) |
| Limited | 3 (8.1) | 3 (12.5) | 0 |
| Extensive | 20 (54.1) | 13 (54.2) | 7 (53.9) |
| No | 5 (13.5) | 4 (16.7) | 1 (7.7) |
| Expired < 100 days post-HCT | 9 (24.3) | 4 (16.7) | 5 (38.5) |
| Any GVHD (aGVHD/cGVHD) | |||
| Yes | 29 (78.4) | 19 (79.2) | 10 (76.9) |
| No | 8 (21.6) | 5 (20.8) | 3 (23.1) |
| Relapse/ Progression post-HCT | |||
| Yes | 9 (24.3) | 6 (25.0) | 3 (23.1) |
| No | 28 (75.7) | 18 (75.0) | 10 (76.9) |
| Vital Status post-HCT | |||
| Alive | 20 (54.1) | 15 (62.5) | 5 (38.5) |
| Dead | 17 (45.9) | 9 (37.5) | 8 (61.5) |
| Cause of Death | |||
| Disease Progression | 6 (16.2) | 4 (44.4) | 2 (25.0) |
| Infection | 6 (16.2) | 3 (33.3) | 3 (37.5) |
| multi-organ failure | 2 (5.4) | 1 (11.1) | 1 (12.5) |
| aGVHD | 1 (2.7) | 0 | 1 (12.5) |
| cGVHD | 1 (2.7) | 0 | 1 (12.5) |
| secondary malignancy (duodenal) | 1 (2.7) | 1 (11.1) | 0 |
aGVHD–acute graft-versus-host disease, NA–not applicable, cGVHD–chronic graft-versus-host disease, HCT–hematopoietic cell transplant